Cytosorbents Corp (NASDAQ:CTSO) – Analysts at Zacks Investment Research reduced their Q2 2020 earnings per share (EPS) estimates for shares of Cytosorbents in a report released on Tuesday, July 28th. Zacks Investment Research analyst M. Marin now anticipates that the medical research company will post earnings per share of ($0.07) for the quarter, down from their previous forecast of ($0.06). Zacks Investment Research also issued estimates for Cytosorbents’ Q4 2020 earnings at ($0.06) EPS.

Other research analysts also recently issued research reports about the company. ValuEngine downgraded Cytosorbents from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. BidaskClub raised Cytosorbents from a “hold” rating to a “buy” rating in a research note on Tuesday, June 30th. B. Riley reissued a “buy” rating on shares of Cytosorbents in a research note on Thursday, July 23rd. Maxim Group initiated coverage on Cytosorbents in a research note on Thursday, May 7th. They set a “buy” rating and a $14.00 target price for the company. Finally, HC Wainwright boosted their target price on Cytosorbents from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Cytosorbents presently has an average rating of “Buy” and a consensus price target of $15.25.

CTSO stock opened at $9.58 on Friday. The company has a market cap of $346.71 million, a PE ratio of -17.41 and a beta of 0.57. The business has a 50-day simple moving average of $9.81 and a 200 day simple moving average of $7.68. Cytosorbents has a 52 week low of $3.49 and a 52 week high of $11.74. The company has a quick ratio of 3.10, a current ratio of 3.27 and a debt-to-equity ratio of 0.54.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported ($0.10) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.04. Cytosorbents had a negative net margin of 62.65% and a negative return on equity of 165.86%. The firm had revenue of $8.71 million during the quarter, compared to analysts’ expectations of $7.14 million.

Several large investors have recently added to or reduced their stakes in the company. Skylands Capital LLC grew its holdings in shares of Cytosorbents by 5.9% during the second quarter. Skylands Capital LLC now owns 1,192,800 shares of the medical research company’s stock worth $11,809,000 after purchasing an additional 66,500 shares during the last quarter. Creative Planning grew its holdings in shares of Cytosorbents by 8.7% during the second quarter. Creative Planning now owns 34,735 shares of the medical research company’s stock worth $344,000 after purchasing an additional 2,773 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Cytosorbents by 74.4% during the second quarter. SG Americas Securities LLC now owns 18,777 shares of the medical research company’s stock worth $186,000 after purchasing an additional 8,013 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Cytosorbents by 51.9% during the first quarter. Royal Bank of Canada now owns 8,857 shares of the medical research company’s stock worth $68,000 after purchasing an additional 3,027 shares during the last quarter. Finally, Zebra Capital Management LLC bought a new stake in shares of Cytosorbents during the first quarter worth about $87,000. Institutional investors own 27.46% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Featured Story: How does quantitative easing work?

Earnings History and Estimates for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.